Aubrey de Grey had a large mouse study of combinations of antiaging treatments. They did show that combination treatments did ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...

Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...

CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the expansion of SELVA, its Phase 3 clinical trial of ...

The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

Palvella Therapeutics is set to expand its 24-week Phase III SELVA trial to include subjects aged three to five years old for ...

H.C. Wainwright reaffirmed a Buy rating and a $38.00 price target for Palvella Therapeutics (NASDAQ: PVLA) shares. Currently trading at $15.72, the stock has shown strong momentum with a 31% gain year ...

除TD Cowen外，H.C. Wainwright也重申了对Palvella Therapeutics的积极立场，维持买入评级和38.00美元的目标价。该公司特别关注QTORIN rapamycin在治疗皮肤静脉畸形方面的潜力，以实现公司的销售目标。

If you’ve been on the internet recently, you’ve likely encountered Bryan Johnson’s meticulously optimized, data-driven quest ...